期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 9, 期 1, 页码 79-95出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712590802631862
关键词
angiogenin; antibody therapy; CD22(+) lymphoma; CD30(+) lymphoma; human pancreatic RNase; ImmunoRNase; immunotherapy; immunotoxins; Onconase; ranpirnase; ribonucleases; RNase A family; RNases; targeted RNase; tumor therapy
资金
- German National Genome Research Network [NGFN2, OIGRO428]
Immunotoxins combining antibody specificity with bacterial or plant toxins are limited by their strong immunogenicity and non-specific toxicity. Ribonucleases of the RNase A protein superfamily provide a solution to address these issues because they show potent antineoplastic activity on cell internalization but do not show appreciable immunogenicity or non-specific toxicity. Their therapeutic value is demonstrated by RNase derived from the frog (Rana pipiens), Onconase (R) (ONC, Alfacell, Inc., New Jersey, USA), the first and only RNase being evaluated in clinical trials at present. Conjugation or fusion of RNases to tumor specific antibodies is a promising approach to further boost tumor cell killing of these compounds. This review focuses on 'targeted RNases/immunoRNases' as promising novel anticancer therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据